Original ArticleCatheter Ablation of Atrial Fibrillation in Patients with Concomitant Left Ventricular Impairment: a Systematic Review of Efficacy and Effect on Ejection Fraction
Introduction
Heart failure (HF) and atrial fibrillation (AF) are intricately coupled clinical conditions. AF is common amongst HF patients, and is particularly prevalent in patients with higher NYHA functional class [1]. At least one in four newly-diagnosed AF patients may suffer from HF, and the development of AF in HF patients represents a significant risk factor for mortality [2], [3].
In the past decade, catheter ablation has become established as a therapy for symptomatic, drug-refractory AF [4], [5]. Current guidelines cautiously support AF ablation for patients with co-existent left ventricular impairment, suggesting that AF ablation may be considered in selected symptomatic patients with HF and/or reduced ejection fraction [4], [5].
As such, the role of catheter ablation in AF patients with concomitant LVSD is not only an area of uncertainty, but an important management issue in the care of HF patients. There has recently been a significant increase in the number of studies reporting clinical outcomes in AF and HF. The primary purpose of our study was to evaluate the efficacy and safety of AF ablation LVSD patients, as well as the impact of AF ablation on left ventricular ejection fraction (LVEF) and quality of life (QOL).
Section snippets
Methods
We searched the scientific literature in PubMed, Scopus, Embase, using the search terms “atrial fibrillation AND ablation AND (ventricular dysfunction OR heart failure OR cardiomyopathy)”. This search was supplemented by hand-searching of bibliographies and narrative reviews of AF and HF. The primary criterion for inclusion were studies reporting outcomes for percutaneous catheter ablation outcomes of AF in HF patients. Criteria for left ventricular systolic dysfunction case definition were
Search and Synthesis of Literature
2484 unique citations were identified. 2333 were excluded on general criteria, and 151 were selected for detailed secondary review. From this group, a total of 19 publications met inclusion criteria. Included studies were published between 2004-2014.
Study Design and Characteristics
Study quality was limited in that the majority of studies were non-randomised, including single centre case series [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], with four randomised control trials [21], [22], [23],
Discussion
Catheter ablation has become an established therapy for the treatment of symptomatic AF [4]. However, the role of AF ablation in the management of patients with co-existent left ventricular systolic dysfunction is an area of uncertainty. We performed a systematic review of the published literature to assess the outcomes of catheter ablation in patients with comorbid AF and LVSD.
We found that:
- •
AF ablation is able to restore sinus rhythm in LVSD patients, with satisfactory single procedure and
Disclosures
Sources of Funding: Dr Ganesan is supported by an Australian Early Career Health Practitioner Fellowship of the National Health and Medical Research Council of Australia. Dr Pathak and Twomey are supported by Leo J. Mahar Electrophysiology Scholarships from the University of Adelaide. Dr Mahajan is supported by the Leo J. Mahar Lectureship from the University of Adelaide. Dr Lau is supported by a Postdoctoral Fellowship from the National Health and Medical Research Council of Australia. Dr
Conflicts of Interest
Dr Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, St Jude Medical, Sanofi-Aventis and Merck, Sharpe and Dohme. Dr Sanders reports having received lecture and/or consulting fees from Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, Merck, Sharpe and Dohme, Biotronik and Sanofi-Aventis. Dr Sanders reports having received research funding from Medtronic, St Jude Medical, Boston Scientific, Biotronik and Sorin.
References (37)
- et al.
Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function
J Am Coll Cardiol.
(2004) - et al.
Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation
J Am Coll Cardiol.
(2008) - et al.
A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure
Journal of the American College of Cardiology.
(2013) - et al.
Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation
J Am Coll Cardiol.
(2009) - et al.
Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction
Am J Cardiol
(2010) Substrate for development of atrial fibrillation in patients with congestive heart failure: are we close to the answer?
Heart Rhythm.
(2009)- et al.
Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation
J Am Coll Cardiol
(2010) - et al.
Atrial fibrillation and heart failure: treatment considerations for a dual epidemic
Circulation.
(2009) - et al.
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study
Circulation.
(2003) - et al.
Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis
Internal Medicine Journal.
(2010)
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation
Heart Rhythm.
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
Eur Heart J.
Long-term results of transcatheter atrial fibrillation ablation in patients with impaired left ventricular systolic function
Journal of Cardiovascular Electrophysiology.
Sinus rhythm restoration by catheter ablation in patients with long-lasting atrial fibrillation and congestive heart failure: impact of the left ventricular ejection fraction improvement on the implantable cardioverter defibrillator insertion indication
Europace.
Catheter ablation in selected patients with depressed left ventricular ejection fraction and persistent atrial fibrillation unresponsive to current cardioversion
Europace.
Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation
Europace.
Ablation of atrial fibrillation in patients with heart failure: reversal of atrial and ventricular remodelling
Hellenic J Cardiol.
Cited by (54)
Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes
2020, Heart Failure ClinicsAtrial <sup>18</sup>F-FDG uptake is related to permanent atrial fibrillation: Will substrate-based patient selection improve outcome?
2020, Journal of Nuclear Cardiology
- 1
denotes equal contribution